| Category | Transactions | TotalQuantity | Revenue | Discounts | SalesTax | OtherTax |
|---|---|---|---|---|---|---|
| Non-Medical | 134,928,083 | 4,316,330,112 | $4,170,070,518 | $545,973,161 | $133,536,645 | $15,322,886,788 |
| Medical | 70,986,358 | 267,615,574 | $2,377,370,979 | $394,094,487 | $73,737,649 | $299,063,497 |
| NA | 16,060,461 | 486,172,535 | $455,740,174 | $60,504,672 | $15,821,517 | $256,755,881 |
Medical vs Non-Medical Cannabis Sales
Comparing inventory, revenue, and discounts
This analysis compares medical and non-medical cannabis sales, tracking quantity sold, discounts applied, and total revenue impact.
The Bottom Line Up Front
Washington’s medical cannabis system is under-utilized, even as medical consumers continue to spend more on average. Meanwhile, the adult-use market is maturing into a competitive, discount-driven retail ecosystem.
Better tax alignment and medical program participation could protect:
patient affordability
small-business revenue stability
supply chain resilience
Overview
Washington’s cannabis economy has always operated as a dual-track market — medical patients and adult-use consumers share the same shelves, but they behave very differently.
With over 221 million transaction records analyzed through November 2025, the Evergreen Canna Ledger examined how revenue, discounting, and taxation vary between the two consumer groups.
Sales Summary by Category
Table of Important Medical Cannabis Dates
| Date | Event Label |
|---|---|
| 2022-01-01 | Post-CCR Migration Stabilization |
| 2023-07-23 | Medical Program Changes & Consolidated Rules |
| 2024-01-01 | New Tax/Fee Updates Begin (EPR fees + supply chain compliance shifts) |
| 2025-07-01 | Retail License & Packaging Rule Adjustments |
Revenue Comparison
What we see in the timeline:
Early 2022 shows sporadic volatility as MJ-Freeway stabilization continued.
Sales surge through 2024–2025, driven by:
Tourism recovery
Product innovation (vapes, solventless, edibles)
Low-cost flower competition
A sharp correction in mid-2025 as discounting rises and margins tighten.
Discount Analysis
| Category | Avg Discount Per Unit | Avg Total Discount |
|---|---|---|
| Medical | $5.53 | $5.55 |
| Non-Medical | $4.04 | $4.05 |
Medical patients receive fewer discount opportunities and tend to buy higher-value products per visit (e.g., high-CBD tinctures, RSO).
This suggests pricing may create access barriers for some medical consumers — a key policy insight.
Tax Analysis Summary
| Category | Avg Sales Tax | Avg Other Tax |
|---|---|---|
| Medical | $1.03 | $4.12 |
| Non-Medical | $0.97 | $3.78 |
Despite eligibility for reduced taxes, many patients do not register as medical users at the point of sale — possibly due to:
administrative hurdles
stigma
limited retailer participation in the medical program
That leaves vulnerable consumers paying near-adult-use tax levels for medicine.
What All This Means for Operators & Policymakers.
| Insight | Implication |
|---|---|
| Medical consumers generate higher revenue per transaction | Continued growth in wellness-aligned SKUs |
| Adult-use volatility increases during economic uncertainty | Price compression pressures margins |
| Medical tax benefit usage remains low | Opportunity for reforms that improve access |
Join the Discussion
Your insights help drive better transparency and smarter policy in Washington’s cannabis industry.